Two Analogues of Fenarimol Show Curative Activity in an Experimental Model of Chagas Disease

Citations Over TimeTop 10% of 2013 papers

Abstract

Chagas disease, caused by the protozoan parasite Trypanosoma cruzi (T. cruzi), is an increasing threat to global health. Available medicines were introduced over 40 years ago, have undesirable side effects, and give equivocal results of cure in the chronic stage of the disease. We report the development of two compounds, 6 and (S)-7, with PCR-confirmed curative activity in a mouse model of established T. cruzi infection after once daily oral dosing for 20 days at 20 mg/kg 6 and 10 mg/kg (S)-7. Compounds 6 and (S)-7 have potent in vitro activity, are noncytotoxic, show no adverse effects in vivo following repeat dosing, are prepared by a short synthetic route, and have druglike properties suitable for preclinical development.

Related Papers

• → Evidence of Trypanosoma cruzi II infection in Colombian chagasic patients(2008)58 cited
• → Discovery and Optimization of a Compound Series Active against Trypanosoma cruzi, the Causative Agent of Chagas Disease(2020)12 cited
• → The reception by French physicians of Chagas' discovery of Trypanosoma cruzi and American trypanosomiasis (1909-1925)(2009)3 cited
• → Discovery and Optimization\nof a Compound Series Active\nagainst <i>Trypanosoma cruzi</i>, the Causative Agent of\nChagas Disease(2020)
• → In Vitro Evaluation of Arylsulfonamide Derivatives against Trypanosoma cruzi(2023)